Information Provided By:
Fly News Breaks for November 19, 2019
PGNY
Nov 19, 2019 | 06:02 EDT
Goldman Sachs analyst Stephen Tanal initiated coverage of Progyny with a Buy rating and $33 price target. The analyst expects the company to take "considerable share of the fast-growing" fertility benefits market. The macro backdrop remains supportive of growth, and Progyny's "unique approach" to the fertility benefit drives high rates of patient satisfaction, Tanal tells investors in a research note.
News For PGNY From the Last 2 Days
There are no results for your query PGNY